Skip to main content
NCBI home page
BMC Ophthalmology logoLink to BMC Ophthalmology
. 2011 Jun 14;11:14. doi: 10.1186/1471-2415-11-14

Incidence of new coding for dry eye and ocular infection in open-angle glaucoma and ocular hypertension patients treated with prostaglandin analogs: Retrospective analysis of three medical/pharmacy claims databases

Gail F Schwartz 1,✉, Sameer Kotak 2, Jack Mardekian 2, Joel M Fain 2
PMCID: PMC3146461  PMID: 21672240

Abstract

Background

To investigate the clinical relevance of two different preservative formulations, we compared 1-year incidence rates of additional coding of dry eye, ocular infection, or ocular surface disease (either dry eye or ocular infection) in open-angle glaucoma and ocular hypertension patients newly treated with latanoprost with benzalkonium chloride (BAK) or with travoprost-Z with SofZia®.

Methods

This was a retrospective study of three U.S.-based patient-centric medical/pharmacy claims databases (MedStat, PharMetrics, i3-Ingenix). Patients were eligible if they filled a prescription for latanoprost or travoprost-Z between October 2006 and Q2 2008 (prescription date = index date) AND were continuously enrolled 6 months prior through 12 months after the index date AND had any open-angle glaucoma or ocular hypertension diagnosis within 90 days prior to the index date AND did not have an ocular surface disease diagnosis during the 180 days prior to the index date AND if they had not had a prescription for the index agent in the 180 days prior to the index date. Time to incidence of new coding for ocular surface disease in the first year post-index was estimated with a composite endpoint: diagnosis of dry eye or ocular infection by ICD-9-CM or Current Procedural Terminology code OR by prescription for cyclosporine ophthalmic emulsion or ocular antibiotics.

Results

In all, 15,933 patients were treated with latanoprost and 7670 with travoprost-Z. Over 1 year, 4.3% of latanoprost and 4.5% of travoprost-Z patients were identified with dry eye (p = 0.28), and 10.9% and 11.1%, respectively, were identified with an ocular infection (p = 0.79). The 1-year incidence of new coding for ocular surface disease also was similar across treatments (13.9% vs 14.3%, respectively; p = 0.48).

Conclusions

The retrospective analysis of three large prescription databases revealed that open-angle glaucoma and ocular hypertension patients newly treated with latanoprost preserved with BAK or travoprost-Z preserved with SofZia did not differ statistically in rates of dry eye, ocular infection, or ocular surface disease (either dry eye or ocular infection) during the first year post-index. Claims-based analyses are limited by nonrandomization and the inability to account for over-the-counter use or samples.

Background

Ocular surface disease is an umbrella term that encompasses both dry eye disease (e.g., aqueous deficient and evaporative) and non-dry eye disease (e.g., lid-related diseases, allergic conjunctivitis, infective and noninfective keratitis) [1]. A question remains as to whether commercial preservatives used in ocular hypotensive eye drops administered by patients with open-angle glaucoma or ocular hypertension affect the occurrence of ocular surface disease, in particular the occurrence of dry eye and/or ocular infection, when the clinical evidence from randomized, controlled trials suggests there is no clear link [2-4].

All preservatives have the potential to cause corneal and conjunctival changes, including possibly dry eye. The prevalence of clinically diagnosed dry eye among glaucoma patients in general and among those treated with ocular hypotensive agents containing benzalkonium chloride (BAK) remains unclear [5,6], although relatively few patients included in pivotal trials of bimatoprost, latanoprost, and travoprost, all of which contain BAK, reported dry eye (1% to 4% for latanoprost and travoprost; 3% to 10% for bimatoprost) [2-4]. Moreover, removing BAK from a prostaglandin analog or using an alternative preservative may not reduce the occurrence of dry eye. A double-masked, randomized, parallel group trial [7] that compared the safety and tolerability of travoprost with BAK versus that of travoprost-Z with SofZia®, an ionic buffered system composed of boric acid, propylene glycol, sorbitol, and zinc chloride, found no statistically or clinically significant between-treatment differences with regard to ocular adverse events or tolerability; the prevalence of dry eye was 1.7% with travoprost-Z versus 2.0% with travoprost [8].

With regard to infection, preservatives protect against potentially dangerous bacterial and fungal organisms that may be introduced inadvertently into multiple-dose containers during eye drop instillation, especially with larger size bottles (e.g., 5 mL, 7.5 mL) [9-11]. The bactericidal and fungicidal activity of preservatives helps ensure ocular safety, an especially important consideration given the increase in bacterial resistance to antibiotic treatment of ocular infections [12,13] and the dramatic rise in the incidence of fungal keratitis [14-17]. Although these reported outbreaks of fungal keratitis occurred in contact lens wearers and we are not aware of published data suggesting that different preservatives may be associated with outbreaks with chronic use of ocular hypotensive medications, the dramatic rise in the incidence of the condition highlights the importance of using preservatives that comply with stringent standards of antimicrobial activity in multidose containers.

To investigate the clinical relevance of two different preservative formulations, we compared 1-year incidence rates of additional coding of dry eye, ocular infection, and ocular surface disease, defined as either dry eye or ocular infection, in open-angle glaucoma and ocular hypertension patients newly treated with latanoprost with BAK or travoprost-Z with SofZia.

Methods

This was a retrospective analysis of information from three U.S.-based patient-centric medical and pharmacy claims databases: MedStat, PharMetrics, and i3-Ingenix. Together, these databases contain information from managed care organizations consisting of over 123.5 million patients. The data represent a systematic sample of commercial health plan information obtained from managed care plans throughout the U.S. It is paid claims data, which by definition is information collected by the medical plans from medical service providers to facilitate the adjudication and payment of health insurance benefits on behalf of the plan's enrolled members. The databases were deidentified in accordance with Health Insurance Portability and Accountability Act requirements prior to being made available for analysis in this study; use of these data in health research is exempt from institutional review board review.

Condition identifiers are provided in Table 1. Open-angle glaucoma and ocular hypertension were defined by ICD-9-CM codes, while dry eye, ocular infection, and the ocular surface disease composite endpoint reflecting either dry eye or ocular infection were defined by ICD-9-CM codes, Current Procedural Terminology [CPT] codes and/or prescriptions.

Table 1.

Identifiers of Conditions

Condition Identifier Heading
Open-angle glaucoma ICD-9-CM: Open-angle glaucoma
365.11
Ocular hypertension ICD-9-CM: Ocular hypertension
365.04
Dry eye Prescription* Restasis (cyclosporine ophthalmic emulsion)
ICD-9-CM:
370.20
370.21 Superficial keratitis, unspecified
370.33 Punctate keratitis
370.8† Keratoconjunctivitis Sicca not specified as Sjogren's
370.9† Other forms of keratitis
372.20† Unspecified keratitis
372.39† Blepharoconjunctivitis
375.15 Other conjunctivitis
710.2 Tear film insufficiency unspecified
CPT: Sicca syndrome
68760
68761 Closure of lacrimal punctum; by thermocauterization ligation or laser surgery
Closure of lacrimal punctum by plug
Infection Prescription* Bacitracin (bacitracin); Bleph-10; Cetamide; Chibroxin; Ciloxan (ciprofloxacin); Erythromycin; Levaquin (levofloxacin); Neomycin; Neosporin; Oculflox (ofloxacin); Ocusulf-10; Sodium Sulamyd; Sulf-10; Tobradex; Vigamox (moxifloxacin); Zymar
ICD-9-CM:
370.00
370.8† Corneal ulcer unspecified
370.9† Other forms of keratitis
372.00 Unspecified keratitis
372.03 Acute conjunctivitis
372.20† Other mucupurulent conjunctivitis
372.30 Blepharoconjunctivitis
372.39† Conjunctivitis unspecified
Other conjunctivitis
Ocular Surface Disease Composite Endpoint Any identifier of dry eye or ocular infection
Open in a new tab

*Generic drug name in parenthesis where applicable.

†ICD-9-CM code applicable for both dry eye and infection.

CPT = Current Procedural Terminology; ICD-9-CM = International Classification of Diseases, Ninth Revision, Clinical Modification.

The derivation of the analysis population is summarized in Table 2. The patient's fill date for latanoprost or travoprost-Z was considered to be the index date. Patients were eligible for inclusion if the index date was between October 2006, when travoprost-Z was introduced in the U.S., and the second quarter of 2008 AND if they were continuously enrolled 6 months prior through 12 months after the index date AND if they had any open-angle glaucoma or ocular hypertension diagnosis within 90 days prior to the index date AND if they did not have a diagnosis of ocular surface disease during the 180 days prior to the index date AND if they had not had a prescription for the index agent in the 180 days prior to the index date. Of the more than 264,000 potentially eligible patients across the three databases, 23,603 were included in the analysis population.

Table 2.

Derivation of analysis population

Database
MedStat PharMetrics i3-Ingenix Total
All patients in the database 41,105,604 >60,000,000 22,689,623 >123,795,227
 And filled prescription for latanoprost or travoprost-Z 10/2006 - Q2/2008 152,961 69,298 42,424 264,683
 And continuous enrollment 6 months prior through 12 months after index date 84,871 35,447 23,091 143,409
 And any open-angle glaucoma or ocular hypertension* diagnosis within 90 days prior to index date 31,760 14,713 9107 55,580
 And no ocular surface disease* during 180 days prior to index date 28,711 12,833 7597 49,141
 And no prescription for the index agent in 180 days prior to index date 15,154 4151 4298 23,603
Open in a new tab

*Defined in Table 1.

Index date = date of initial prescription for latanoprost or travoprost-Z; Q2 = second quarter.

Frequencies of patients in the latanoprost and travoprost-Z groups diagnosed with dry eye, ocular infection, or ocular surface disease during 1 year of follow-up were tabulated separately and compared using Cochran-Mantel-Haenszel tests stratified by claims database and by indicator of condition. Kaplan-Meier and Cox proportional hazards survival analyses of time to occurrence of dry eye, ocular infection, or ocular surface disease were performed. The statistical significance of between-group differences in time to occurrence of each endpoint was assessed using the Cox proportional hazards model that included treatment, age, gender, Charlson Comorbidity Index (which is used routinely to characterize the health status of patients in administrative databases [18]), geographic region, diagnosis, and claims database as predictors. P-values for age and Charlson Comorbidity Index are from an analysis of variance model that included treatment, database, and treatment by database interaction. P-values for diagnosis, gender, and geographic region are from Cochran-Mantel-Haenszel tests stratified by database.

Results

The analysis set included 15,933 patients prescribed latanoprost and 7670 patients prescribed travoprost-Z. Patients prescribed the two prostaglandins were similar with regard to gender and geographic region; a larger proportion of latanoprost-treated patients was diagnosed with ocular hypertension, and, on average, those in the latanoprost group were older and had a higher score on the Charlson Comorbidity Index (Table 3).

Table 3.

Patient characteristics

Characteristic Latanoprost
N = 15,933		 Travoprost-Z
N = 7670		 p-value
Diagnosis, n (%) <0.0001
 Open-angle glaucoma 13,918 (87.4) 6837 (89.1)
 Ocular hypertension 2015 (12.6) 833 (10.9)
Sex, n (%)* 0.55
 Female 8413 (52.8) 4008 (52.3)
 Male 7519 (47.2) 3662 (47.7)
Age, years: Mean ± SD 67.4 ± 13.3 66.3 ± 13.0 <0.0001
Charlson Comorbidity Index:
 Mean ± SD 0.74 ± 1.25 0.67 ± 1.15 <0.0001
Geographic region† 0.17
 Northeast 2914 (18.3) 1071 (14.0)
 Midwest 5004 (31.4) 2440 (31.9)
 South 5270 (33.1) 2756 (36.0)
 West 2728 (17.1) 1387 (18.1)
Open in a new tab

*Missing data for 1 latanoprost patient.

†Missing data for 17 latanoprost and 16 travoprost-Z patients.

SD = standard deviation.

Over 1 year, 4.3% of latanoprost and 4.5% of travoprost-Z patients were identified with dry eye (p = 0.28), and 10.9% and 11.1%, respectively, were identified with an ocular infection (p = 0.79; Table 4). The 1-year incidence of new coding for ocular surface disease also was similar across treatments (13.9% vs 14.3%, respectively; p = 0.48). Among the 3,306 ocular surface disease events, there was no statistically significant between-treatment difference in proportions of patients developing the condition when it was indicated by diagnosis, CPT code, or prescription (Table 5).

Table 4.

One-year incidence of new coding for dry eye ocular infection, or both dry eye and ocular infection,* n (%)

Index drug Total patients Dry eye Ocular infection Both
Latanoprost 15,933 600 (3.8) 1670 (10.5) 60 (0.4)
Travoprost-Z 7670 298 (3.9) 821 (10.7) 23 (0.3)
p-value - 0.48 0.86 0.31
Open in a new tab

*Categories are not mutually exclusive. See Table 1 for definitions of dry eye and ocular infection.

Table 5.

One-year incidence of new coding for ocular surface disease (OSD) by indicator of condition, n (%)

OSD indicated by*
Total Diagnosis (ICD-9-CM) CPT Code Prescription
Index drug No OSD OSD No OSD OSD No OSD OSD No OSD OSD
Latanoprost 13,723 (86.1) 2210 (14.0) 15,127 (94.9) 806 (5.1) 15,849 (99.5) 84 (0.5) 14,275 (89.6) 1658 (10.4)
Travoprost-Z 6574 (85.6) 1096 (14.3) 7279 (94.9) 391 (5.1) 7616 (99.3) 54 (0.7) 6832 (89.1) 838 (10.9)
p-value 0.48 0.66 0.13 0.42
Open in a new tab

*Categories are not mutually exclusive. See Table 1 for definition of ocular surface disease composite endpoint.

CPT = Current Procedural Terminology; ICD-9-CM = International Classification of Diseases, Ninth Revision, Clinical Modification.

Kaplan-Meier survival curves for time to dry eye, infection, and ocular surface disease were nearly identical for latanoprost and travoprost-Z overall (Figure 1 A, B, and 1C, respectively) and when stratified by database (Figure 2 A, B, and 2C, respectively. Curves also were virtually identical when ocular surface disease was indicated by diagnosis, CPT code, or prescription (Figure 3A, B, and 3C, respectively). Mean time to an ocular surface disease event among patients with events was approximately 5 months in both groups (latanoprost: 164.0 ± 104.8 days; travoprost-Z: 160.4 ± 104.3 days).

Figure 1.

Figure 1

Open in a new tab

Days to dry eye (A), infection (B), and ocular surface disease composite endpoint (C) by treatment group

Figure 2.

Figure 2

Open in a new tab

Days to dry eye (A), infection (B), and ocular surface disease composite endpoint (C) by database

Figure 3.

Figure 3

Open in a new tab

Days to ocular surface disease indicated by diagnosis (A), procedures (CPT code) (B), or prescription (C) by treatment group

Discussion

When choosing an ocular hypotensive agent for patients with open-angle glaucoma or ocular hypertension, physicians should consider the efficacy of candidate medications, their tolerability and side effect profiles, as well as any concomitant ocular and systemic conditions the patient may have [19]. With the advent of new preservative formulations, it also is essential that clinicians familiarize themselves with the body of evidence regarding the long-term safety and efficacy of the preservatives contained in ophthalmic solutions. Our analysis of three large prescription databases found that open-angle glaucoma and ocular hypertension patients newly treated with latanoprost containing BAK were not significantly more likely to develop dry eye, ocular infection, or ocular surface disease (either dry eye or ocular infection) as evidenced by additional coding for these disorders during the first year of treatment than were patients newly treated with travoprost-Z containing SofZia.

BAK, which has been used as a preservative for more than 50 years, is among the few preservatives that meet the rigorous criteria required by both the United States Pharmacopoeia (USP) and the European Pharmacopoeia [20,21]. SofZia, approved by the Food and Drug Administration in 2006, also meets USP standards, but little is published about its pharmacokinetics and pharmacodynamics [22]. There is contradicting evidence concerning the relationship of BAK and the development of ocular surface disorders. Dose-dependent, BAK-induced epithelial cellular damage has been found in studies of cultured corneal [23] and conjunctival cells [24] as well as in studies of cats and rabbits [25-28], but these studies may not accurately reflect ocular surface conditions in humans. Others [29-33] have shown that the levels of BAK contained in ophthalmic solutions are unlikely to cause clinically important negative corneal effects. Determining the relationship between BAK and dry eye in glaucoma patients is made more problematic by the fact that the incidence of both conditions increases with age [34,35], although history of glaucoma has not been found to be an independent risk factor for dry eye [36].

While preservative-free ocular hypotensive eye drops generally have been associated with fewer side effects [37-42] and better stability of the tear film [40,43] than drops containing a preservative, preservatives are added to ophthalmic preparations that are instilled multiple times in order to control microbial growth and to prevent the consequences associated with the use of contaminated solutions [21,44]. Serious infections can result from the instillation of contaminated eye preparations. Pathogenic contamination of eye drops is a significant risk factor for several complications, including infectious keratitis [21], although we know of no published data suggesting that different preservatives may be associated with outbreaks of this condition with chronic use of glaucoma medications.

The importance of determining the clinical impact of alternative preservatives in ocular hypotensive eye drops reflects the need to reduce the risk of ocular infection while limiting side-effects such as dry eye that might reduce patient adherence and persistence. Although we found no statistically significant difference in the 1-year incidence of ocular surface disease in more than 23,000 patients treated with either latanoprost or travoprost-Z, other studies [45-48] have yielded disparate results, at least in part due to differences in methodologies and measures, and, in some cases [46-48], to small samples and low power to detect differences if they existed. For example, a multicenter, investigator-masked, parallel-group study [47] of patients with glaucoma or ocular hypertension who had been treated with latanoprost monotherapy for at least 4 weeks were randomized to receive monotherapy with bimatoprost with BAK (n = 35), latanoprost with BAK (n = 38), or travoprost with SofZia (n = 33). Across 3 months of follow-up, no significant between-treatment differences were noted in conjunctival hyperemia scores, corneal staining, or tear breakup time. A randomized, double-blind study [48] compared tolerability in 33 patients treated with latanoprost in one eye and travoprost-Z in the other. Eyes were assessed by one examiner every 3 to 4 weeks for 3 months, and patients rated the extent of differences between eyes in ocular dryness/irritation at the beginning and at the end of the study. In this small sample, eyes treated with travoprost-Z had significantly more corneal staining (p = 0.025) and showed a trend toward more dryness and irritation symptoms than those treated with latanoprost (p = 0.095). A prospective, 8-week, unmasked, single-center study [46] of 40 eyes of 20 patients with low baseline tear break-up times who were switched from latanoprost to travoprost-Z found a significant increase (p < 0.001) in mean tear break-up time and a significant decrease (p < 0.001) in the mean Ocular Surface Disease Index score. The authors noted that the study focused on patients with low initial tear break-up times, limiting generalizability to the entire population of patients with dry eye; the lack of blinding, the absence of a comparison group, and the potential for regression to the mean also were limitations. A prospective, open-label, 3-month study [45] of 691 patients switched to travoprost-Z from latanoprost or bimatoprost due to tolerability issues found clinically and statistically significant improvement in ocular surface disease symptoms. The study was limited by the facts that open-label, switch designs do not control for expectations of improvement on the part of both patients and physicians, and by its short follow-up time frame.

As with all research, the present study has both strengths and limitations. Primary strengths include the large sample size. However, this was a retrospective analysis in which patients were not randomized, a basic limitation of all claims-based analyses. Patient use of over-the-counter products and samples as well as off-label use of topical corticosteroids to treat dry eye were not reflected in the database. The proportion of patients recommended to use artificial tears cannot be determined using a database analysis. Because this was a claims-based analysis rather than a clinical trial, we could not directly measure dry eye syndrome but instead measured the addition of a second code for one of many ocular surface diseases; we cannot estimate the frequency with which physicians omitted a relevant second code or patients added an artificial tear supplement without the knowledge of the physician. Identifying dry eye using CPT and ICD-9-CM codes may select for more severe cases of the condition. It is possible that the populations of patients using the two compounds could have been different since travoprost-Z has been specifically marketed and may have been chosen in some individuals who might already have mild, non-coded ocular surface disease prior to 180 days or who had a history of ocular surface symptoms that were not specifically coded for in the study. Not accounted for were any diagnosis that was made >180 days prior to the index date and that might not have been coded for as the subject developed glaucoma or the physician only coded for one, not two diseases which is quite common. In addition, although a glaucoma specialist (GFS) reviewed and approved the codes used to identify the clinical endpoints evaluated, other specialists might argue for the inclusion of other identifiers and/or the exclusion of some used herein; to our knowledge, there is no widely accepted set of identifiers for the general conditions of dry eye, ocular infection, or ocular surface disease.

Conclusion

Results of the present retrospective analysis of three large prescription databases suggest that open-angle glaucoma and ocular hypotensive patients newly treated with latanoprost with BAK or with travoprost-Z containing SofZia do not differ statistically in rates of coding for dry eye, ocular infection, or ocular surface disease (either dry eye or ocular infection), during the first year post-index. Prospective, randomized, adequately powered comparisons of similarly effective ocular hypotensive agents with different preservatives are needed to more definitively answer the question of the clinical relevance of alternative preservative formulations.

Competing interests

Dr. Schwartz was a paid consultant to Pfizer Inc in connection with the design and conduct of the study, including development of the manuscript. Dr. Fain, Dr. Mardekian, and Mr. Kotak are employees of Pfizer Inc. The study was supported by Pfizer Inc, New York, New York, USA.

Authors' contributions

All authors participated in the study design, interpretation of data, and critical revision of the manuscript for important intellectual content, and all read and approved the final manuscript. SK provided study supervision, and JM facilitated acquisition and analysis of data from databases.

Pre-publication history

The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-2415/11/14/prepub

Contributor Information

Gail F Schwartz, Email: schwartzgf@aol.com.

Sameer Kotak, Email: sameer.kotak@pfizer.com.

Jack Mardekian, Email: jack.mardekian@pfizer.com.

Joel M Fain, Email: joel.m.fain@pfizer.com.

Acknowledgements

Editorial support, including contributing to the first draft of the manuscript, revising the paper based on author feedback, and styling the paper for journal submission, was provided by Jane G. Murphy, PhD, of Zola Associates and was funded by Pfizer Inc, New York, New York. The results of this study were presented in part at the Annual Meeting of the Association for Research in Vision and Ophthalmology, May 1 - 6, 2010, in Fort Lauderdale, Florida, USA, and at the World Ophthalmology Congress 2010, June 5 - 9, 2010, in Berlin, Germany.

References

  1. International Dry Eye Workshop. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye Workshop (2007) Ocul Surf. 2007;5:75–92. doi: 10.1016/s1542-0124(12)70081-2. [DOI] [PubMed] [Google Scholar]
  2. Lumigan® [package insert] Irvine, CA: Allergan, Inc.; 2004.
  3. Travatan® [package insert] Fort Worth, TX: Alcon Laboratories, Inc.; 2005.
  4. Xalatan® [package insert] New York, NY: Pfizer Inc.; 2003.
  5. Ali FS, Akpek EK. Glaucoma and dry eye. Ophthalmology. 2009;116:1232. doi: 10.1016/j.ophtha.2008.12.034. [DOI] [PubMed] [Google Scholar]
  6. Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma. 2008;17:350–355. doi: 10.1097/IJG.0b013e31815c5f4f. [DOI] [PubMed] [Google Scholar]
  7. Lewis RA, Katz GJ, Weiss MJ, Landry TA, Dickerson JE, James JE, Hua SY, Sullivan EK, Montgomery DB, Wells DT, Bergamini MV. Travoprost BAC-free Study Group. Travoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacy. J Glaucoma. 2007;16:98–103. doi: 10.1097/01.ijg.0000212274.50229.c6. [DOI] [PubMed] [Google Scholar]
  8. Travatan Z Medical Review. U.S. Food and Drug Administration Center for Drug Evaluation and Research. Silver Spring, MD; 2006. p. 30. [Google Scholar]
  9. Kaur IP, Lal S, Rana C, Kakkar S, Singh H. Ocular preservatives: associated risks and newer options. Cutan Ocul Toxicol. 2009;28:93–103. doi: 10.1080/15569520902995834. [DOI] [PubMed] [Google Scholar]
  10. Geyer O, Bottone EJ, Podos SM, Schumer RA, Asbell PA. Microbial contamination of medications used to treat glaucoma. Br J Ophthalmol. 1995;79:376–379. doi: 10.1136/bjo.79.4.376. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Schein OD, Hibberd PL, Starck T, Baker AS, Kenyon KR. Microbial contamination of in-use ocular medications. Arch Ophthalmol. 1992;110:82–85. doi: 10.1001/archopht.1992.01080130084030. [DOI] [PubMed] [Google Scholar]
  12. Bertino JS. Impact of antibiotic resistance in the management of ocular infections. Clin Ophthalmol. 2009;3:507–521. doi: 10.2147/opth.s5778. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Marangon FB, Miller D, Muallem MS, Romano AC, Alfonso EC. Ciprofloxacin and levofloxacin resistance among methicillin-sensitive Staphylococcus aureus isolates from keratitis and conjunctivitis. Am J Ophthalmol. 2004;137:453–458. doi: 10.1016/j.ajo.2003.10.026. [DOI] [PubMed] [Google Scholar]
  14. Alfonso EC, Cantu-Dibildox J, Munir WM, Miller D, O'Brien TP, Karp CL, Yoo SH, Forster RK, Culbertson WW, Donaldson K, Rodila J, Lee Y. Insurgence of Fusarium keratitis associated with contact lens wear. Arch Ophthalmol. 2006;124:941–947. doi: 10.1001/archopht.124.7.ecs60039. [DOI] [PubMed] [Google Scholar]
  15. Centers for Disease Control. Morbidity and Mortality Weekly Report. 2006. http://www.cdc.gov/mmwr/pdf/wk/mm55d410.pdf Accessed June 28, 2010.
  16. Margolis TP, Whitcher JP. Fusarium-A new culprit in the contact lens case. JAMA. 2006;296:985–987. doi: 10.1001/jama.296.8.985. [DOI] [PubMed] [Google Scholar]
  17. Chang DC, Grant GB, O'Donnell K, Wannemuehler KA, Noble-Wang J, Rao CY, Jacobson LM, Crowell CS, Sneed RS, Lewis FMT, Schaffzin JK, Kainer MA, Genese CA, Alfonso EC, Jones DB, Srinivasan A, Fridkin SK, Park BJ. for the Fusarium Keratitis Investigation Team. Multistate outbreak of Fusarium keratitis associated with use of a contact lens solution. JAMA. 2006;296:953–963. doi: 10.1001/jama.296.8.953. [DOI] [PubMed] [Google Scholar]
  18. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613–619. doi: 10.1016/0895-4356(92)90133-8. [DOI] [PubMed] [Google Scholar]
  19. American Academy of Ophthalmology. Primary Open-Angle Glaucoma, Preferred Practice Pattern. San Francisco, CA: American Academy of Ophthalmology; 2005. [Google Scholar]
  20. Abelson MB, Fink K. How to handle BAK talk. Rev Ophthalmol. 2002;9:52–54. [Google Scholar]
  21. Charnock C. Are multidose over-the-counter artificial tears adequately preserved? Cornea. 2006;25:432–437. doi: 10.1097/01.ico.0000183538.53017.69. [DOI] [PubMed] [Google Scholar]
  22. Kahook MY. Travoprost Z ophthalmic solution with sofZia: clinical safety and efficacy. Expert Rev Ophthalmol. 2007;2:363–368. doi: 10.1586/17469899.2.3.363. [DOI] [Google Scholar]
  23. Cha SH, Lee JS, Oum BS, Kim CD. Corneal epithelial cellular dysfunction from benzalkonium chloride (BAC) in vitro. Clin Exp Ophthalmol. 2004;32:180–184. doi: 10.1111/j.1442-9071.2004.00782.x. [DOI] [PubMed] [Google Scholar]
  24. De Saint Jean M, Brignole F, Bringuier AF, Bauchet A, Feldmann G, Baudouin C. Effects of benzalkonium chloride on growth and survival of Chang conjunctival cells. Invest Ophthalmol Vis Sci. 1999;40:619–630. [PubMed] [Google Scholar]
  25. Burstein NL. Preservative cytotoxic threshold for benzalkonium chloride and chlorhexidine digluconate in cat and rabbit corneas. Invest Ophthalmol Vis Sci. 1980;19:308–313. [PubMed] [Google Scholar]
  26. Noecker RJ, Herrygers LA, Anwaruddin R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea. 2004;23:490–496. doi: 10.1097/01.ico.0000116526.57227.82. [DOI] [PubMed] [Google Scholar]
  27. Whitson JT, Cavanagh HD, Lakshman N, Petroll WM. Assessment of corneal epithelial integrity after acute exposure to ocular hypotensive agents preserved with and without benzalkonium chloride. Adv Ther. 2006;23:663–671. doi: 10.1007/BF02850305. [DOI] [PubMed] [Google Scholar]
  28. Xiong C, Chen D, Liu J, Liu B, Li N, Zhou Y, Liang X, Ma P, Ye C, Ge J, Wang Z. A rabbit dry eye model induced by topical medication of a preservative benzalkonium chloride. Invest Ophthalmol Vis Sci. 2008;49:1850–1856. doi: 10.1167/iovs.07-0720. [DOI] [PubMed] [Google Scholar]
  29. Goldberg I, Li XY, Selaru P, Paggiarino D. A 5-year, randomized, open-label safety study of latanoprost and usual care in patients with open-angle glaucoma or ocular hypertension. Eur J Ophthalmol. 2008;18:408–416. doi: 10.1177/112067210801800315. [DOI] [PubMed] [Google Scholar]
  30. Khoh-Reiter S, Jessen BA. Evaluation of the cytotoxic effects of ophthalmic solutions containing benzalkonium chloride on corneal epithelium using an organotypic 3-D model. BMC Ophthalmol. 2009;9:5. doi: 10.1186/1471-2415-9-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Lass JH, Eriksson GL, Osterling L, Simpson CV. the Latanoprost Corneal Effects Study Group. Comparison of the corneal effects of latanoprost, fixed combination latanoprost-timolol, and timolol: a double-masked, randomized, one-year study. Ophthalmology. 2001;108:264–271. doi: 10.1016/S0161-6420(00)00531-5. [DOI] [PubMed] [Google Scholar]
  32. Stewart WC, Stewart JA, Jenkins JN, Jackson AL. Corneal punctate staining with latanoprost, bimatoprost, and travoprost in healthy subjects. J Glaucoma. 2003;12:475–479. doi: 10.1097/00061198-200312000-00006. [DOI] [PubMed] [Google Scholar]
  33. Thygesen J, Aaen K, Theodorsen F, Kessing SV, Prause JU. Short-term effect of latanoprost and timolol eye drops on tear fluid and the ocular surface in patients with primary open-angle glaucoma and ocular hypertension. Acta Ophthalmol Scand. 2000;78:37–44. doi: 10.1034/j.1600-0420.2000.078001037.x. [DOI] [PubMed] [Google Scholar]
  34. Friedman DS, Wolfs RC, O'Colmain BJ, Klein BE, Taylor HR, West S, Leske MC, Mitchell P, Congdon N, Kempen J. Eye Diseases Prevalence Research Group. Prevalence of open-angle glaucoma among adults in the United States. Arch Ophthalmol. 2004;122:532–538. doi: 10.1001/archopht.122.4.532. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. McCarty CA, Bansal AK, Livingston PM, Stanislavsky YL, Taylor HR. The epidemiology of dry eye in Melbourne, Australia. Ophthalmology. 1998;105:1114–1119. doi: 10.1016/S0161-6420(98)96016-X. [DOI] [PubMed] [Google Scholar]
  36. Moss SE, Klein R, Klein BE. Prevalence of and risk factors for dry eye syndrome. Arch Ophthalmol. 2000;118:1264–1268. doi: 10.1001/archopht.118.9.1264. [DOI] [PubMed] [Google Scholar]
  37. Jaenen N, Baudouin C, Pouliquen P, Manni G, Figueiredo A, Zeyen T. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol. 2007;17:341–349. doi: 10.1177/112067210701700311. [DOI] [PubMed] [Google Scholar]
  38. Martone G, Frezzotti P, Tosi GM, Traversi C, Mittica V, Malandrini A, Pichierri P, Balestrazzi A, Motolese PA, Motolese I, Motolese E. An in vivo confocal microscopy analysis of effects of topical antiglaucoma therapy with preservative on corneal innervation and morphology. Am J Ophthalmol. 2009;147:725–735. doi: 10.1016/j.ajo.2008.10.019. [DOI] [PubMed] [Google Scholar]
  39. Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol. 2002;86:418–23. doi: 10.1136/bjo.86.4.418. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Baudouin C. Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma. Acta Ophthalmol. 2008;86:716–726. doi: 10.1111/j.1755-3768.2008.01250.x. [DOI] [PubMed] [Google Scholar]
  41. Easty DL, Nemeth-Wasmer G, Vounatsos JP, Girard B, Besnainou N, Pouliquen P, Delval L, Rouland JF. Comparison of a non-preserved 0.1% T-Gel eye gel (single dose unit) with a preserved 0.1% T-Gel eye gel (multidose) in ocular hypertension and glaucomatous patients. Br J Ophthalmol. 2006;90:574–578. doi: 10.1136/bjo.2005.080424. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Uusitalo H, Chen E, Pfeiffer N, Brignole-Baudouin F, Kaarniranta K, Leino M, Puska P, Palmgren E, Hamacher T, Hofmann G, Petzold G, Richter U, Riedel T, Winter M, Ropo A. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication. Acta Ophthalmol. 2010;88:329–336. doi: 10.1111/j.1755-3768.2010.01907.x. [DOI] [PubMed] [Google Scholar]
  43. Baudouin C, de Lunardo C. Short term comparative study of topical 2% carteolol with and without benzalkonium chloride in healthy volunteers. Br J Ophthalmol. 1998;82:39–42. doi: 10.1136/bjo.82.1.39. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Yee RW. The effect of drop vehicle on the efficacy and side effects of topical glaucoma therapy: a review. Curr Opin Ophthalmol. 2007;18:134–139. doi: 10.1097/ICU.0b013e328089f1c8. [DOI] [PubMed] [Google Scholar]
  45. Henry JC, Peace JH, Stewart JA, Stewart WC. Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy. Clin Ophthalmol. 2008;2:613–621. doi: 10.2147/opth.s3881. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Horsley MB, Kahook MY. Effects of prostaglandin analog therapy on the ocular surface of glaucoma patients. Clin Ophthalmol. 2009;3:291–295. doi: 10.2147/opth.s5328. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Whitson JT, Trattler WB, Matossian C, Williams J, Hollander DA. Ocular surface tolerability of prostaglandin analogs in patients with glaucoma or ocular hypertension. J Ocul Pharmacol Ther. 2010;26:287–292. doi: 10.1089/jop.2009.0134. [DOI] [PubMed] [Google Scholar]
  48. Townley JR, Reilly C. Dry eye and irritation comparison of latanoprost 0.005% with preservative benzalkonium chloride (BAC) versus travoprost 0.004% without BAC. Invest Ophthalmol Vis Sci. 2009;50:E-Abstract 4651. [Google Scholar]

Articles from BMC Ophthalmology are provided here courtesy of BMC

RESOURCES